Overview

Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of intravitreal ranibizumab injection versus low-fluence PDT in the treatment of chronic CSC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jang Won Heo
Collaborator:
Novartis Korea Ltd.
Treatments:
Lactitol
Ranibizumab
Verteporfin